Check out your Company Bowl for anonymous work chats.
University of Louisville Health Adopts Paige AI-enabled Cancer Detection Software for Enhanced Cancer Detection. University of Louisville (UofL) Health, a leading academic health system based in Louisville, Kentucky, has deployed a full suite of Paige AI-enabled digital pathology software to improve diagnostic confidence, efficiency, and patient care during routine cancer diagnosis.

University of Louisville Health Adopts Paige AI-enabled Cancer Detection Software for Enhanced Cancer Detection
Paige Announces Executive Leadership Appointments! Paige, the global leader in AI-based diagnostic software in pathology, today announced that it has appointed Andy Moye, Ph.D., as Chief Executive Officer and Jill Stefanelli, Ph.D., as President and Chief Business Officer.

Paige Announces Executive Leadership Appointments
Paige Named to the 2021 CB Insights Digital Health 150–List of Most Innovative Digital Health Startups. This recognizes the monumental achievements of our Paige team over the past year, including landing the first-ever FDA approval for an AI product in pathology, completing our Series C financing and achieving numerous business development and commercialization milestones. We are proud of our team, whose work has positioned Paige for strong growth in 2022, delivering on our mission to build the next generation computational technology that unlocks insights from each tissue sample for doctors to optimize patient outcomes. Paige was previously named to the CB Insights Digital Health 150 in 2019 and 2020 – every year since the annual list was first compiled.

Digital Health 150: The Digital Health Startups Transforming the Future of Healthcare | CB Insights Research
Paige receives the first-ever Medtech Innovation Briefing (MIB) for a digital pathology product from the National Institute for Heath Care Excellence (NICE).

National Institute for Health and Care Excellence Publishes Medtech Innovation Briefing on Paige Prostate
Paige looks forward to contributing its expertise in computational pathology and collaborating with Perspectum Group to modernize pathology workflows in the clinical trial setting with the ultimate aim of improving the diagnosis and treatment of disease.

Paige and Perspectum Partner to Power Late-Stage Clinical Trials with Digital Pathology
Introducing Paige Prostate - the first AI-based pathology product to receive de novo approval from the U.S. FDA. This achievement is the culmination of more than a decade of work and a testament to the dedication of our team and collaborators. We’re excited to pave the path forward for a new class of diagnostic software that can potentially improve how we diagnose cancer and ultimately save lives.

Paige Receives First Ever FDA Approval for AI Product in Digital Pathology
We are excited to announce a new collaboration with Quest Diagnostics to advance AI-generated pathology products that can deliver faster, more accurate and more informed clinical insights to patients than what is possible today.

Quest Diagnostics and Paige Form Collaboration to Advance AI-generated Pathology Insights to Improve Cancer Diagnosis and Care
Paige together with University of Oxford, have won the prestigious Phase 4 Artificial Intelligence in Health and Care award delivered by the NHS Accelerated Access Collaborative! Thousands of patients will benefit from the £36 million award to test state-of-the-art AI technology. Led by University of Oxford, Paige will help transform the way pathologists detect, grade and measure tumors in biopsies obtained from the prostate of patients at risk of prostate cancer. Congratulations to all awardees and the NHSX in its commitment to revolutionize healthcare in the UK!

£36 million boost for AI technologies to revolutionise NHS care
Paige Secures Financing from KKR for Total Series C Funding Round of Over $125 Million. Paige, a global leader in AI-based diagnostic software in pathology, today announced that KKR, a leading global investment firm, joined Casdin Capital and Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as co-leads in its Series C financing round, bringing the round to over $125 million. Paige will use this new capital to expand its geographic footprint as it accelerates the development of AI-based clinical applications, biomarkers and diagnostics. Additional investors in the Series C round include Catalio Capital Management, existing investors and other funds, as previously announced.

Paige Secures Financing from KKR for Total Series C Funding Round of Over $125 Million
Beware of scams: if you were contacted via Telegram, please know that we do not recruit via that platform nor do we use text messages to make initial contact with candidates. We encourage you to apply directly to open positions via Glassdoor or our website: https://paige.ai/careers/